Trending NewsTrending NewsNASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $31.12 -2.39 (-7.13%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$30.91 -0.21 (-0.69%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Celldex Therapeutics Stock (NASDAQ:CLDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Celldex Therapeutics alerts:Sign Up Key Stats Today's Range$30.41▼$33.5950-Day Range$31.12▼$44.8752-Week Range$22.10▼$45.14Volume4.24 million shsAverage Volume1.34 million shsMarket Capitalization$2.44 billionP/E RatioN/ADividend YieldN/APrice Target$61.92Consensus RatingModerate Buy Company Overview Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company’s research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits. Celldex’s lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis. The company also maintains additional clinical and preclinical programs targeting immune pathways and cancer biology. Celldex does not have a broadly marketed commercial product and remains focused primarily on research, clinical development and regulatory advancement. Founded in the 1980s, Celldex has evolved into a biotechnology company specializing in antibody discovery and development. It is headquartered in New Jersey and conducts development activities through collaborations and clinical programs that may involve research sites in the United States and other regions. Anthony S. Marucci serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Celldex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCLDX MarketRank™: Celldex Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 593rd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCelldex Therapeutics has a consensus price target of $61.92, representing about 99.0% upside from its current price of $31.12.Amount of Analyst CoverageCelldex Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celldex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($4.17) to ($4.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celldex Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.61% of the float of Celldex Therapeutics has been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 12.23, which indicates bearish sentiment.Change versus previous monthShort interest in Celldex Therapeutics has recently increased by 14.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.93 News SentimentCelldex Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Celldex Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for CLDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.20% of the stock of Celldex Therapeutics is held by insiders.Percentage Held by InstitutionsCelldex Therapeutics has minimal institutional ownership at this time.Read more about Celldex Therapeutics' insider trading history. Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDX Stock News HeadlinesHC Wainwright Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $64.00September 24 at 1:56 AM | americanbankingnews.comCantor Fitzgerald Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) StockSeptember 24 at 1:56 AM | americanbankingnews.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 24 at 1:00 AM | Paradigm Press (Ad)Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?September 23 at 8:50 AM | insidermonkey.comCLDX stock slumps 11% – this analyst sees nearly 90% upside, calls phase 3 trial safety concerns ‘misplaced’September 22 at 10:49 PM | msn.comCelldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria TrialsSeptember 22 at 10:49 PM | finance.yahoo.comCelldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria TranscriptSeptember 22 at 4:00 PM | seekingalpha.comCelldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - SlideshowSeptember 22 at 3:00 PM | seekingalpha.comSee More Headlines CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $27.16 at the start of the year. Since then, CLDX stock has increased by 14.6% and is now trading at $31.12. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.12. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $0.74 million. When did Celldex Therapeutics' stock split? Celldex Therapeutics's stock reverse split on the morning of Monday, February 11th 2019.The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' top institutional shareholders include Wellington Management Group LLP (12.15%), Assenagon Asset Management S.A. (1.00%), Braidwell LP (0.56%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi and Diane C Young. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings8/06/2026Today9/24/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CLDX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CIK744218 Webwww.celldex.com Phone(908) 200-7500Fax908-454-1911Employees198Year Founded1983Price Target and Rating Average Price Target for Celldex Therapeutics$61.92 High Price Target$100.00 Low Price Target$34.00 Potential Upside/Downside+99.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$258.76 million Net MarginsN/A Pretax Margin-190,220.86% Return on Equity-52.35% Return on Assets-47.61% Debt Debt-to-Equity RatioN/A Current Ratio11.82 Quick Ratio11.82 Sales & Book Value Annual Sales$158 thousand Price / Sales15,467.43 Cash FlowN/A Price / Cash FlowN/A Book Value$7.93 per share Price / Book3.92Miscellaneous Outstanding Shares78,530,000Free Float74,446,000Market Cap$2.44 billion OptionableOptionable Beta0.84 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CLDX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
